NASDAQ:RLAY Relay Therapeutics Q1 2025 Earnings Results & Report $17.41 -0.54 (-3.01%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$17.40 0.00 (-0.03%) As of 10/8/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Relay Therapeutics beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 5, 2025. The company reported EPS of -$0.46 versus the -$0.50 consensus estimate, while revenue of $7.68 million topped the $0.01 million estimate by $7.67 million. Revenue decreased 23.0% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 5, 2025TimeAfter Market ClosesConference Call4:00 PM ET Relay Therapeutics EPS ResultsActual EPS-$0.46Consensus EPS -$0.50Beat/MissBeat by +$0.04One Year Ago EPS-$0.62EPS Beat Rate5 of last 8 quartersRelay Therapeutics Revenue ResultsActual Revenue$7.68 millionExpected Revenue$0.01 millionBeat/MissBeat by +$7.67 millionYoY Revenue Growth-23.00%Upcoming EarningsRelay Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Relay Therapeutics Q1 2025 Earnings FAQ Did Relay Therapeutics beat earnings estimates for Q1 2025? Relay Therapeutics (NASDAQ:RLAY) reported earnings of -$0.46 per share for Q1 2025, beating the consensus estimate of -$0.50. The report was announced on Monday, May 5, 2025. What was Relay Therapeutics' revenue for Q1 2025? Relay Therapeutics reported revenue of $7.68 million for Q1 2025, against a consensus estimate of $0.01 million. When is Relay Therapeutics' next earnings date? Relay Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Relay Therapeutics on the company's earnings history page. Relay Therapeutics Earnings HeadlinesRelay Therapeutics Insider Sold Shares Worth $329,322, According to a Recent SEC Filing2 hours ago | marketscreener.comMRelay Therapeutics (RLAY) Stock Looks Fully Priced On Book ValueOctober 8 at 6:26 PM | uk.finance.yahoo.comThe Executive Order That Quietly Changed What Your Dollar MeansOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Is Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?October 8 at 6:26 PM | finance.yahoo.comKrystal Biotech (NASDAQ:KRYS) and Relay Therapeutics (NASDAQ:RLAY) Head-To-Head SurveyOctober 8 at 6:15 AM | americanbankingnews.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Stock Has Consensus Price Target of $25.92 According to BrokeragesSeptember 28, 2026 | americanbankingnews.comSee More Relay Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Relay Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relay Therapeutics and other key companies, straight to your email. Email Address About Relay TherapeuticsRelay Therapeutics (NASDAQ:RLAY) is a clinical-stage biotechnology company focused on discovering and developing medicines for diseases driven by genetically defined targets, particularly in oncology. The company uses its proprietary Dynamo platform, which combines structural biology, computational modeling, machine learning and medicinal chemistry to study how proteins move and to identify potential drug-binding sites that may be difficult to address with conventional approaches. Relay’s pipeline has included targeted cancer therapies such as RLY-2608, an investigational oral inhibitor designed to selectively target PI3K-alpha mutations, and RLY-4008 (lirafugratinib), an investigational FGFR2 inhibitor developed for cancers with specific FGFR2 alterations. The company evaluates its candidates through clinical studies and may pursue commercialization and development collaborations as programs advance. Founded in 2016 and headquartered in Cambridge, Massachusetts, Relay Therapeutics conducts research and clinical development activities intended to support the global treatment of cancer and other serious diseases. Sanjiv Patel serves as the company’s president and chief executive officer.View Relay Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
